sarcoidosis%20-%20pulmonary
SARCOIDOSIS - PULMONARY
Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Sarcoidosis%20-%20pulmonary Management

Follow Up

General Surveillance Principles

  • Sarcoidosis patients should be monitored regularly
  • Monitoring should include a review of symptoms, physical exam, CXR & lung function tests
    • Perform other tests as necessary based on organ involvement
  • Monitor & treat patients for complications of sarcoidosis & related conditions (eg aspergilloma, osteoporosis, hypercalcemia, hypercalciuria)
  • Patients who have undergone therapy should be monitored for 3 years after cessation of treatment
  • Intermittent monitoring (every 3-6 months) is recommended for patients on TNF-alpha inhibitor therapy

Monitoring Intervals Based on Disease Stage

Stage 1

  • Initially every 6 months then once a year if stable

Stage 2, 3, 4

  • Initially every 3-6 months; monitor indefinitely

Serious extrapulmonary involvement, regardless of radiographic stage

  • Monitor indefinitely
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.